Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.53 |
| ▸ | MDM4 | O15151 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30141763 | 0.91 | SLC17A5 (0.49) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL30141774 | 0.87 | SLC17A5 (0.52) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL18708304 | 0.87 | SLC17A5 (0.52) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL31682399 | 0.86 | SLC17A5 (0.53) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL21664276 | 0.86 | SLC17A5 (0.53) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL16801787 | 0.86 | SLC17A5 (0.53) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL31682400 | 0.85 | SLC17A5 (0.53) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL16801838 | 0.84 | SLC17A5 (0.55) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL19888241 | 0.84 | SLC17A5 (0.58) | SLC17A5MDM4TP53TLR2CASP3 | |
| SCHEMBL4719374 | 0.83 | TLR2 (0.56) | SLC17A5MDM4TP53TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282827-A1 | LIPIDATED POLYMYXIN ANALOGUES | AUCKLAND UNISERVICES LTD (NZ) | 2025-09-11 | — | — | US | disclosed |
| EP-4384533-A1 | LIPIDATED POLYMYXIN ANALOGUES | Auckland Uniservices Limited (NZ) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023017450-A1 | LIPIDATED POLYMYXIN ANALOGUES | AUCKLAND UNISERVICES LIMITED (NZ) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282827-A1 | LIPIDATED POLYMYXIN ANALOGUES | PHOSPHO1, PCTP, PTMS | SLC17A5 1388/4885MDM4 4349/4885TP53 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.